Li Ning, Junshi Biosciences CEO

Jun­shi Bio­sciences touts lung can­cer da­ta as it looks to ex­pand PD-1 la­bel in Chi­na again

In a bid to get an­oth­er PD-1 reg­i­men ap­proved in Chi­na, Jun­shi Bio­sciences has spelled out Phase III da­ta show­ing that its drug cut the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.